Tom Newsom‐Davis

Chelsea and Westminster Hospital NHS Foundation Trust — United Kingdom

Medicine · Health Sciences

19h-index2.3kcitations58works2.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(17), Viral-associated cancers and disorders(17), Lymphoma Diagnosis and Treatment(12), Cancer Immunotherapy and Biomarkers(9), Lung Cancer Diagnosis and Treatment(6)

Publications58 total

Radiotherapy for Unresectable Locally Advanced NSCLC: A Practical Multidisciplinary Approach to Challenging Scenarios From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee
Journal of Thoracic Oncology·2025
1890P Real-world survival outcomes for docetaxel-containing regimens for patients with locally advanced or metastatic non-small cell lung cancer in England who have progressed on current standard of care
Annals of Oncology·2025
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study
JTO Clinical and Research Reports·2024· 4 citedOpen Access
OA02.03 Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study
Journal of Thoracic Oncology·2024· 8 citedOpen Access
1215P United Kingdom (UK) real world study of adjuvant osimertinib in resected EGFR mutated lung cancer
Annals of Oncology·2024· 1 citedOpen Access
Validated machine learning tools to distinguish immune checkpoint inhibitor, radiotherapy, COVID-19 and other infective pneumonitis
Radiotherapy and Oncology·2024· 10 citedOpen Access
84 National Real World Study of Adjuvant Osimertinib in Resected EGFR Mutated Lung Cancer
Lung Cancer·2024
95 Lorlatinib in advanced ALK-rearranged NSCLC – real-world experience in a UK population
Lung Cancer·2024
27 Characteristics of lung cancer diagnosed through a Rapid Diagnostic Clinic
Lung Cancer·2024
Efficacy of carboplatin–etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis
Therapeutic Advances in Medical Oncology·2024· 5 citedOpen Access
1116P United Kingdom real-world experience of sotorasib in KRAS G12C mutant non-small cell lung cancer: A British thoracic oncology group review
Annals of Oncology·2022· 3 cited
9P Final results from TAIL: Updated long-term safety and efficacy of atezolizumab (atezo) in a diverse population of patients (pts) with previously treated advanced NSCLC
Annals of Oncology·2022Open Access
Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19
JAMA Network Open·2022· 58 citedOpen Access
Clinical predictors of long-term efficacy of first-line pembrolizumab monotherapy in non-small cell lung cancer (NSCLC): an interim analysis of real-world data
Lung Cancer·2022
Association of primary and community care services with emergency visits and hospital admissions at the end of life in people with cancer: a retrospective cohort study
BMJ Open·2022· 10 citedOpen Access
Increased emergency presentation of new lung cancer diagnoses and less treatment: a COVID legacy
Lung Cancer·2021
Pleomorphic lung carcinoma – a rare response to a rare tumour
Lung Cancer·2021
Real-world outcomes using pembrolizumab plus pemetrexed-platinum in 1st line metastatic NSCLC compared to results reported from KEYNOTE-189: a multicentre experience
Lung Cancer·2021
Lung cancer treatment during a pandemic: how have multi-disciplinary teams changed?
Lung Cancer·2021
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score
Journal for ImmunoTherapy of Cancer·2021· 39 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Mark Bower(23), Mark Nelson(13), Brian Gazzard(11), Justin Stebbing(11), Christina Thirlwell(8), Nicola Steele(5), D.J. Hughes(3), Alvin Lee(3), Jaishree Bhosle(3), Sundhiya Mandalia(3), Tom Powles(3), S Mandalia(3), Sanjay Popat(3), Riyaz Shah(3), T. Geldart(3), Alastair Greystoke(3), Joanne Evans(3), Lennard Y. W. Lee(2), Jean‐Baptiste Cazier(2), Roland Arnold(2)